Pharma Foods International Co (PMDSF) Fair Value & Analysis
Healthcare · US · Market cap $186M
Pharma Foods International Co
PMDSF · US
Fair value as of: Jul 18, 2026
From 21 valuation models · updated 24 days ago
Share price +1.2% over the past month.
A solid business, screening 85% undervalued on our models.
What matters now
- The price is below even our cautious bear case ($9.65). The market is more pessimistic than our downside scenario.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (21 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
21‑month range $5.39 – $6.40 · fair‑value band $9.65 – $14.54 · the $6.40 price screens below the $11.84 fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Pharma Foods International Co (PMDSF) currently trades at $6.40, while our model-based Fair Value estimate is $11.84, implying the stock looks roughly 85.0% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Pharma Foods International Co generated revenue of $67.0B at a net margin of 0.6%. Revenue declined 5.0% year over year. It earns a return on equity of 4.2%. Net debt stands at $1.2B. Fundamentals as of Jul 18, 2026
Our scenario range runs from $9.65 (bear case) to $14.54 (bull case); at $6.40, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 85%, PMDSF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 21 models by family
Widest divergence: DCF Models ($11.84) versus Asset-Based ($1.67). Highest evidence: Growth DCF (80).
Notify me when PMDSF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. It also focuses on biomedical drug discovery of antibody and peptide drugs targeting diseases, including autoimmune, cancer, and inflammatory. The company was founded in 1997 and is headquartered in Kyoto, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2024 · reported fiscal years
Pharma Foods International Co reported revenue of $62.1B in FY2024 versus $60.2B in FY2022, a compound +1.6%/yr. Reported net income was $3.2B in FY2024.
Watch PMDSF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Pharma Foods International Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharma Foods International Co (PMDSF) overvalued or undervalued?
What is the fair value of PMDSF?
What is the quality score of PMDSF?
What is the revenue of Pharma Foods International Co (PMDSF)?
What is the net profit margin of PMDSF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharma Foods International Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.